Focusing on the development of new drugs for the treatment of inflammatory diseases
Temisis is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing a strong inflammatory component.
Temisis is committed to developing small therapeutic molecules to fulfil unmet needs in pathologies involving IL-17/23 axis of inflammation.
Our main asset in dermatology, TEM1657, is a brand-new small molecule that shows similar efficacy as market reference corticosteroids at pre-clinical stage to remit psoriasis symptoms but without the common side effects that are associated.
Symptoms are significantly reduced after the first application of TEM1657.
Complete remission of psoriasis symptoms
No erythema – Regulated desquamation – Normal skin thickness.
No side effect
No skin thinning (unlike corticosteroids), no observed side effect on animals in toxicity tests.